2-羟基-2-[2-(三氟甲基)苯基]乙酸 | 339-93-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-2-[2-(三氟甲基)苯基]乙酸
• 中文别名: 1H-吡咯-3-甲醛,2,5-二氢-2,2,5,5-四甲基-4-苯基-
• 英文名称: 2-(trifluoromethyl)mandelic acid
• 英文别名: 2-trifluoromethylmandelic acid；(RS)-a-hydroxy-(2-trifluoromethylphenyl)acetic acid；D-2-trifluoromethyl-mandelic acid；[2-(Trifluoromethyl)phenyl]glycolic acid；2-hydroxy-2-[2-(trifluoromethyl)phenyl]acetic acid
• CAS: 339-93-5
• 化学式: C₉H₇F₃O₃
• 分子量: 220.148
• InChiKey: QNVLFHMMPUBIIN-UHFFFAOYSA-N

物化性质

• 沸点：
  314.5±37.0 °C(Predicted)
• 密度：
  1.481±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  2-羟基-2-[2-(三氟甲基)苯基]乙酸 在 sodium hydroxide 、 二溴亚砜 、 硫酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.17h， 生成 (RS)-[2-cyano-5-(thien-3-ylmethoxy)phenoxy]-(2-trifluoromethylphenyl)acetic acid
  参考文献：
  名称：

  Selective ET_A Antagonists. 5. Discovery and Structure−Activity Relationships of Phenoxyphenylacetic Acid Derivatives

  摘要：

  The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ETA receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ETA antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC50 59 nM, rat aortic ETA). Optimization of 13a led to the identification of 27b, which exhibited an IC50 of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 mu mol/kg) and was duly proposed and accepted as a development candidate.

  DOI：

  10.1021/jm990378b
• 作为产物：
  描述：

  邻三氟甲基苯甲醛 在 盐酸 、 水 、 苄基三甲基氯化铵 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 2-羟基-2-[2-(三氟甲基)苯基]乙酸
  参考文献：
  名称：

  Relationships between the racemic structures of substituted mandelic acids containing 8- and 10-membered hydrogen bonded dimer rings

  摘要：

  研究了27种单取代的扁桃酸的结构，包括它们的几种多态性，以及未取代的扁桃酸本身（两种多态性）的结构相似性。

  DOI：

  10.1039/c4ce01832j

文献信息

• [EN] BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE<br/>[FR] BENZIMIDAZOLES ET BENZOTHIAZOLES UTILISES COMME INHIBITEURS DE LA MAP KINASE
  申请人：LILLY CO ELI

  公开号：WO2004014900A1

  公开（公告）日：2004-02-19

  The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis.

  本发明提供了一种化合物I的激酶抑制剂：其中W代表咪唑、噁唑、吡唑、噻唑或三唑等，这些化合物被苯基或噻吩基取代。所公开的化合物抑制p-38激酶，在转移或类风湿性关节炎的治疗中很有用。
• Relationships between the racemic structures of substituted mandelic acids containing 8- and 10-membered hydrogen bonded dimer rings
  作者：S. J. Coles、A. L. Ellis、K. Leung、J. Sarson、T. L. Threlfall、G. J. Tizzard

  DOI：10.1039/c4ce01832j

  日期：——

  The structures of 27 monosubstituted mandelic acids, including several of their polymorphs, plus unsubstituted mandelic acid itself (two polymorphs) are investigated for structural similarity.

  研究了27种单取代的扁桃酸的结构，包括它们的几种多态性，以及未取代的扁桃酸本身（两种多态性）的结构相似性。

• Photocatalytic Carbinol Cation/Anion Umpolung: Direct Addition of Aromatic Aldehydes and Ketones to Carbon Dioxide
  作者：Shintaro Okumura、Yasuhiro Uozumi

  DOI：10.1021/acs.orglett.1c02592

  日期：2021.9.17

  We have developed a new photocatalytic umpolung reaction of carbonyl compounds to generate anionic carbinol synthons. Aromatic aldehydes or ketones reacted with carbon dioxide in the presence of an iridium photocatalyst and 1,3-dimethyl-2-phenyl-2,3-dihydro-1H-benzimidazole (DMBI) as a reductant under visible-light irradiation to furnish the corresponding α-hydroxycarboxylic acids through nucleophilic

  我们开发了一种新的羰基化合物光催化聚合反应，以生成阴离子甲醇合成子。芳香醛或酮在铱光催化剂和 1,3-二甲基-2-苯基-2,3-二氢-1 H-苯并咪唑 (DMBI) 作为还原剂的存在下与二氧化碳反应，在可见光照射下提供通过将所得的甲醇阴离子与亲电二氧化碳进行亲核加成，生成相应的α-羟基羧酸。
• Anti-viral compounds
  申请人：Eli Lilly and Company

  公开号：US06358971B1

  公开（公告）日：2002-03-19

  The present invention relates to compounds of Formula (I) below, which inhibit the growth of picornaviruses, Hepatitus viruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. wherein: A is phenyl, pyridyl, substituted phenyl, substituted pyridyl, or benzyl; R is hydrogen, COR4, or COCF3; X is N—OH, O, or CHR1; R1 is hydrogen, halo, CN, C1-C4 alkyl, —C≡CH, CO(C1-C4 alkyl), CO2(C1-C4 alkyl), or CONR2R3; R2 and R3 are independently hydrogen or C1-C4 alkyl; A′ is hydrogen, halo, C1-C6 alkyl, benzyl, naphthyl, thienyl, furyl, pyridyl, pyrollyl, COR4, S(O)nR4, or a group of the formula R4 is C1-C6 alkyl, phenyl, or substituted phenyl; n is 0, 1, or 2; R5 is independently at each occurrence hydrogen or halo; m is 1, 2, 3, or 4; and R6 is hydrogen, halo, CF3, OH, CO2H, NH2, NO2, CONHOCH3, C1-C4 alkyl, or CO2(C1-C4 alkyl), C1-C4 alkoxy; or a pharmaceutically acceptable salt thereof.

  本发明涉及以下化合物（I）的公式，它们抑制了小肠病毒、肝炎病毒、肠病毒、心病毒、脊髓灰质炎病毒、A组和B组柯萨奇病毒、回声病毒和门戈病毒的生长。其中：A为苯基、吡啶基、取代苯基、取代吡啶基或苄基；R为氢、COR4或COCF3；X为N—OH、O或CHR1；R1为氢、卤素、CN、C1-C4烷基、—C≡CH、CO（C1-C4烷基）、CO2（C1-C4烷基）或CONR2R3；R2和R3独立地为氢或C1-C4烷基；A′为氢、卤素、C1-C6烷基、苄基、萘基、噻吩基、呋喃基、吡啶基、吡咯基、COR4、S（O）nR4或R4的公式组，其中R4为C1-C6烷基、苯基或取代苯基；n为0、1或2；R5在每次出现时独立地为氢或卤素；m为1、2、3或4；以及R6为氢、卤素、三氟甲基、羟基、CO2H、NH2、NO2、CONHOCH3、C1-C4烷基、或CO2（C1-C4烷基）、C1-C4烷氧基；或其药用可接受盐。
• [EN] PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4 (3H)-ONE UTILISÉS EN TANT QU'ANTAGONISTES DE TRPV4
  申请人：RAQUALIA PHARMA INC

  公开号：WO2021221169A1

  公开（公告）日：2021-11-04

  This invention relates to pyrimidin-4(3H)-one derivatives that act as modulators of the TRPV4 receptor. The present invention also relates to processes for the preparation of novel pyrimidin-4(3H)-one derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain, and urological diseases or disorders.

  这项发明涉及作为TRPV4受体调节剂的嘧啶-4(3H)-酮衍生物。本发明还涉及新型嘧啶-4(3H)-酮衍生物的制备方法，以及它们在治疗各种疾病、综合症和紊乱中的应用，特别是用于治疗炎症、疼痛和泌尿系统疾病或紊乱。